Name: Tesamorelin
Brand: PeptidesDirect
SKU: PD-TESAMORELIN-10MG
Price: 64.99 EUR
Availability: InStock

Question 1

What is Tesamorelin?

Accepted Answer

Tesamorelin is a stabilized GHRH analog consisting of the full 44-amino-acid GHRH sequence with an N-terminal trans-3-hexenoic acid modification. This modification protects against DPP-IV enzymatic cleavage, significantly extending its half-life.

Question 2

How should I store Tesamorelin?

Accepted Answer

Store lyophilized Tesamorelin at -20°C for long-term storage or at 2-8°C for short-term use. Reconstitute with bacteriostatic water and use within 30 days. Keep refrigerated at 2-8°C after reconstitution.

Question 3

What purity is your Tesamorelin?

Accepted Answer

Every batch of Tesamorelin ships with a certificate of analysis from Janoshik Analytical, an independent third-party laboratory, at a minimum purity of 98%. We do not run a lab ourselves: the manufacturer commissions this test, and we pass the report on unchanged, with an online verification link on the product page.

Question 4

How is Tesamorelin different from Sermorelin?

Accepted Answer

Tesamorelin is a full GHRH(1-44) analog with an N-terminal fatty acid stabilizer, giving it a much longer half-life than Sermorelin GHRH(1-29). Tesamorelin is the only GHRH analog with FDA approval, used in HIV-related lipodystrophy research.

Question 5

What has Tesamorelin actually been studied for, in terms of condition, model and species?

Accepted Answer

Tesamorelin has completed human trials in four distinct populations. The largest are HIV patients with visceral fat, and in two later trials liver fat (Falutz et al., N Engl J Med, 2007, PMID 18057338, 412 patients; Falutz et al., J Clin Endocrinol Metab, 2010, PMID 20554713, 806 patients; Stanley et al., JAMA, 2014, PMID 25038357; Stanley et al., Lancet HIV, 2019, PMID 31611038); a smaller trial tested non-HIV obese adults with reduced growth hormone secretion (Makimura et al., J Clin Endocrinol Metab, 2012, PMID 23015655, 60 patients); another tested adults with type 2 diabetes (Clemmons et al., PLoS One, 2017, PMID 28617838, 53 patients); and another tested older adults with normal cognition or mild cognitive impairment (Baker et al., Arch Neurol, 2012, PMID 22869065, 152 patients). The HIV trials are far larger and are the basis of the only regulatory approval; the obesity, diabetes and cognition trials were smaller, investigator-initiated studies that did not lead to any additional approval. No completed trial exists in healthy young adults, general obesity outside a reduced-growth-hormone diagnosis, or for bodybuilding-type goals.

Question 6

In the pivotal phase 3 tesamorelin trials, how long did dosing continue, and was it administered daily?

Accepted Answer

In the pivotal phase 3 trials, adult HIV patients received 2 mg of tesamorelin by subcutaneous injection once daily for 26 to 52 weeks (Falutz et al., N Engl J Med, 2007, PMID 18057338; Falutz et al., J Clin Endocrinol Metab, 2010, PMID 20554713). The trials reported participants' body mass index, not their weight in kilograms, so no paper prints an exact mg per kg figure for this dose. That 2 mg per day regimen is the basis of the FDA-approved label for Egrifta in HIV-associated lipodystrophy, approved November 10, 2010, which makes Tesamorelin one of the few research peptides with a real, regulator-reviewed human dosing history. That FDA-reviewed history is specific to one indication in HIV patients: smaller investigator-initiated trials have tested the same 2 mg dose, or a lower 1 mg dose, in obesity, type 2 diabetes and cognition research, but none of those has led to an approved dosing protocol for any other population or purpose.

Question 7

What did the Tesamorelin trials observe as the outcome, and how quickly did the effect appear?

Accepted Answer

Visceral fat fell significantly within the first 26 weeks in every phase 3 trial: 15.2% versus a 5.0% rise on placebo in the 412-patient trial (P<0.001, Falutz et al., 2007, PMID 18057338), and 24 cm2 versus a 2 cm2 rise on placebo in the 806-patient trial (Falutz et al., 2010, PMID 20554713). IGF-1 rose in parallel by 81 to 108%, depending on the trial, and triglycerides fell alongside the visceral-fat response. In a 61-patient liver-disease trial, hepatic fat fraction fell 4.1 percentage points, a 37% relative drop, over 12 months (Stanley et al., Lancet HIV, 2019, PMID 31611038). Patients who stayed on treatment for 52 weeks kept the visceral-fat loss, but those switched to placebo at 6 months rapidly regained it (Falutz et al., J Acquir Immune Defic Syndr, 2010, PMID 20101189).

Question 8

Does tesamorelin cause joint aches, muscle pain or tingling sensations, and how common were they in the trials?

Accepted Answer

The current FDA-approved label reports injection-site reactions in 25% of tesamorelin patients versus 14% on placebo over the first 26 weeks, and hypersensitivity reactions (itching, redness, flushing, hives, rash) in 4% of patients, with anti-tesamorelin IgG antibodies detectable in 85% of that hypersensitivity subgroup and in 50% of all treated patients by 26 weeks (Egrifta WR prescribing information, DailyMed). The same label's adverse-reaction table reports arthralgia in 13% of tesamorelin patients versus 11% on placebo, and myalgia in 6% versus 2%. A separate mechanistic trial found paresthesia in 21% of patients versus 5% on placebo (Stanley et al., JAMA, 2014, PMID 25038357). A pooled review of the phase 3 program put serious adverse events at under 4% of patients over 26 weeks, most often injection-site reactions, arthralgia, headache and peripheral edema (Dhillon, BioDrugs, 2011, PMID 22050344).

Question 9

What did animal and preclinical studies show about Tesamorelin's safety, separate from the human trials?

Accepted Answer

In preclinical toxicology in pigs, rats and dogs, doses up to 600 microg per kg, about 0.6 mg per kg, given by intravenous or subcutaneous injection for up to 4 months in dogs raised growth hormone and IGF-1 sharply (Ferdinandi et al., Basic Clin Pharmacol Toxicol, 2007, PMID 17214611). At that sustained, supraphysiological exposure, dogs showed reversible liver and kidney changes, anemia, and altered organ weights, which the study attributed to the exaggerated GH/IGF-1 pharmacology rather than direct toxicity of the molecule. Those organ-level findings do not appear in the human trials at the much lower, FDA-approved 2 mg per day dose, but they show that Tesamorelin's core biology carries dose-dependent organ risk in animals at high, sustained exposure.

Question 10

What is not known about Tesamorelin's long-term safety, i.e. what is the honest evidence gap?

Accepted Answer

The longest published human safety data run to about 52 weeks of continuous treatment, in the HIV population (Falutz et al., J Acquir Immune Defic Syndr, 2010, PMID 20101189); no trial in any population has followed patients for more than a year. The FDA label states plainly that lifetime carcinogenicity studies in rodents have not been conducted with tesamorelin acetate and that the effects of prolonged IGF-1 elevation are unknown, which is why the label calls for periodic IGF-1 monitoring and excludes patients with active malignancy, since GH is a known growth factor (Egrifta WR prescribing information, DailyMed). When the drug's EU applicant, Ferrer Internacional, sought European approval, the EMA's CHMP could not conclude on a positive benefit-risk balance, citing insufficient long-term IGF-1 safety data beyond 48 weeks and no cardiovascular-outcome data; the application was withdrawn in June 2012 rather than approved. Smaller trials outside HIV, in obesity, type 2 diabetes and cognition, ran for 10 weeks to 12 months and reported no serious adverse events, but none of them, any more than the HIV trials, has followed patients for years.

Question 11

Is Tesamorelin approved by the FDA, EMA, or any other regulator?

Accepted Answer

In the United States, yes: the FDA approved tesamorelin, brand name Egrifta, on November 10, 2010, specifically to reduce excess visceral abdominal fat in HIV patients with lipodystrophy, based on the phase 3 program described above. It has never been approved in the European Union. Ferrer Internacional filed an EU marketing application for Egrifta in 2011, but withdrew it in June 2012 after the EMA's CHMP raised concerns about insufficient long-term safety data on IGF-1 elevation and the lack of cardiovascular-outcome data. Tesamorelin is therefore an approved prescription drug in the US for one narrow indication, and an unapproved compound everywhere in the EU, including for the indication it was actually studied for.

Question 12

Does the benefit of Tesamorelin persist after stopping, or is continued use required?

Accepted Answer

No, the benefit is not durable. In the 12-month trial, patients switched from tesamorelin to placebo after 6 months rapidly regained the visceral fat they had lost (Falutz et al., J Acquir Immune Defic Syndr, 2010, PMID 20101189). A pooled review of the phase 3 program confirms the same pattern: stopping treatment led to re-accumulation of visceral adipose tissue (Dhillon, BioDrugs, 2011, PMID 22050344). No published trial has tested repeated on-off cycles or what happens to this pattern over years.

Question 13

Who funded the Tesamorelin trials, and does that affect how the evidence should be weighed?

Accepted Answer

The two pivotal phase 3 trials (Falutz et al., N Engl J Med, 2007, PMID 18057338; Falutz et al., J Clin Endocrinol Metab, 2010, PMID 20554713) were run by the drug's manufacturer, Theratechnologies, as part of its own FDA submission, a direct interest in a positive result. The later mechanistic trial on visceral and liver fat (Stanley et al., JAMA, 2014, PMID 25038357) was funded by NIH grants R01DK063639 and K23DK089910, plus Harvard Clinical and Translational Science Center funding, with Theratechnologies stated to have had no role in the study's design, conduct, analysis or manuscript and to have only supplied the study drug, a more independent structure. Both funding sources found broadly consistent effects on visceral and hepatic fat, which is reassuring, but the safety picture, especially anything requiring years of follow-up, still rests mostly on the manufacturer-run program.

Question 14

How does Tesamorelin differ from CJC-1295 or Ipamorelin, since all three are sold as growth-hormone-related peptides?

Accepted Answer

Tesamorelin is a stabilized analog of the full 44-amino-acid GHRH molecule itself, with an added group that blocks the DPP-IV enzyme that normally breaks GHRH down within minutes. CJC-1295 is a different, longer-acting GHRH analog: an industry-sponsored phase 2 trial in HIV-associated visceral obesity (ClinicalTrials.gov NCT00267527, sponsor ConjuChem) was terminated in 2006 and the compound never reached phase 3 or approval. Ipamorelin works through a separate receptor entirely, the ghrelin receptor, rather than the GHRH receptor. Tesamorelin is the only one of the three with completed phase 3 human trials and an FDA-approved label, 2 mg per day, for HIV-associated lipodystrophy; neither CJC-1295 nor Ipamorelin has FDA approval for any indication.

Question 15

Does raising IGF-1 with Tesamorelin affect blood glucose, and is that a diabetes-risk concern?

Accepted Answer

Yes, there is a real, labeled signal: the FDA label reports that 5% of tesamorelin patients developed an HbA1c of 6.5% or higher by week 26 versus 1% on placebo, a statistically significant increased risk of developing diabetes (hazard ratio 3.3, 95% CI 1.4 to 9.6), which is why the label calls for checking glucose status before starting treatment and monitoring it periodically during treatment (Egrifta WR prescribing information, DailyMed). That signal did not show up as a significant difference in the trial-level glucose and insulin summaries reported in the original phase 3 papers (Falutz et al., N Engl J Med, 2007, PMID 18057338; Falutz et al., J Clin Endocrinol Metab, 2010, PMID 20554713), and a separate mechanistic trial found only a transient rise in fasting glucose at 2 weeks that had disappeared by 6 months (Stanley et al., JAMA, 2014, PMID 25038357). A dedicated 12-week trial in patients who already had type 2 diabetes found no significant change in insulin response or glycemic control on tesamorelin (Clemmons et al., PLoS One, 2017, PMID 28617838). No trial, in HIV patients, diabetics, or otherwise, has followed patients long enough or in large enough numbers to rule out a longer-term glucose effect.

Question 16

What does our own third-party CoA show for Tesamorelin, and how can a specific batch be verified?

Accepted Answer

Our current Tesamorelin batch, color code Red, was tested by Janoshik Analytical at 99.36% purity, with 9.82 mg of measured content in the 10 mg vial. Like 43 of our 58 published lab reports, this one was commissioned by the manufacturer rather than by us or by an independent lab we hired directly, and we publish it unedited with that origin stated rather than calling it independent testing. Anyone can check this specific result against Janoshik's own database at verify.janoshik.com using the test ID printed on the report, instead of relying on our word for the numbers. The batch color on the vial label corresponds to this tested batch; it is not a printed lot number or a QR code.

Question 17

Is the Tesamorelin sold as a research peptide the same substance as the pharmaceutical Egrifta?

Accepted Answer

The active molecule is the same 44-amino-acid GHRH analog that was studied in the phase 3 trials and approved by the FDA under the brand name Egrifta. What differs is the product around it: Egrifta is a specific FDA-regulated formulation, dispensed by prescription with a defined delivery kit and mandated physician monitoring of IGF-1 and injection sites, none of which applies to a research-grade vial. Every dose, effect and side-effect figure in these FAQs comes from studies of the approved drug in HIV patients, not from any study of an unregulated research vial.

Question 18

Has Tesamorelin been studied for anything other than HIV-associated fat, such as cognition, general anti-aging, or bodybuilding?

Accepted Answer

Yes, cognition specifically has been tested in human trials, though not in the HIV population this compound is approved for. A 152-person randomized, double-blind, placebo-controlled trial in healthy older adults and adults with mild cognitive impairment found that 20 weeks of tesamorelin, 1 mg per day, improved executive function (P=0.005) and showed a trend toward better verbal memory (P=0.08), alongside a 117% rise in IGF-1 (Baker et al., Arch Neurol, 2012, PMID 22869065). Two later, smaller trials did not confirm a clear benefit: a 73-person, 6-month trial in HIV-positive adults with abdominal obesity found no significant between-group cognitive benefit despite a real reduction in waist circumference (Ellis et al., J Infect Dis, 2025, PMID 39813152), and a 22-person pilot at the same low dose found no significant change on standard cognitive measures, only exploratory brain-connectivity differences (Stewart et al., eNeurologicalSci, 2026, PMID 42382101). No completed human trial has tested tesamorelin for general anti-aging or bodybuilding-type goals in any population; those uses are extrapolated from growth-hormone biology in general, not from a tesamorelin-specific trial.

Question 19

How should tesamorelin be stored before and after reconstitution, and how long does a reconstituted vial stay stable?

Accepted Answer

Keep the unopened, lyophilized vial frozen at -20°C and protected from light until you are ready to reconstitute it; sealed and stored this way, the powder is stable for the long term. Once dissolved in bacteriostatic water, refrigerate the solution at 2 to 8°C, also out of direct light, and avoid repeated freeze-thaw cycles, which stress the peptide more than steady refrigeration does. As practical guidance, consistent with the storage window we give for our other reconstituted lyophilized peptides, use the reconstituted solution within about 4 weeks. No published stability study has measured an exact shelf life for reconstituted tesamorelin specifically, so this is standard peptide-handling practice, not a study finding.

Question 20

How does tesamorelin differ from sermorelin, since both are GHRH-pathway peptides?

Accepted Answer

Both act on the same pituitary GHRH receptor, but the molecules differ substantially. Tesamorelin is the full 44-amino-acid GHRH sequence with an added N-terminal group that blocks the DPP-IV enzyme, which otherwise breaks GHRH down within minutes. Sermorelin is a much shorter fragment, GHRH(1-29), the minimum sequence that still activates the receptor, but it lacks that protective modification, so it is degraded far faster. This stability lines up with tesamorelin's once-daily dosing in the phase 3 trials behind its FDA-approved label (Egrifta); sermorelin was once an FDA-approved drug (Geref), but that approval was later withdrawn, and no approved sermorelin product exists today. This is a structural and evidence-depth comparison, not an efficacy ranking.

Question 21

Why do tesamorelin studies show an effect on visceral fat specifically, rather than subcutaneous fat?

Accepted Answer

Researchers point to basic adipocyte biology, not a tesamorelin-specific finding, as the likely explanation. Visceral fat cells carry a higher density of growth-hormone receptors and respond more strongly to GH-driven lipolysis than subcutaneous fat cells, a difference established in the broader GH literature rather than in the tesamorelin trials themselves. Since tesamorelin works by raising the body's own pulsatile GH output, that receptor difference is the standard explanation offered for why the HIV trials measured a large reduction in visceral fat specifically, alongside comparatively little reported change in subcutaneous fat. This describes the biology behind a finding in one studied patient population, not an outcome promised for anyone using the vial.

Question 22

Did the tesamorelin trials specify a fasting window or time-of-day for dosing, and does that affect the growth-hormone response?

Accepted Answer

No. In the pivotal phase 3 trials and on the FDA label, tesamorelin was given as 2 mg subcutaneously once daily, with no fasting window, no fixed time of day, and no instruction to inject away from meals (Egrifta prescribing information, DailyMed). The notion that timing matters comes from general growth-hormone physiology, where rising glucose and insulin can blunt the pituitary GH pulse a GHRH analog is meant to trigger, not from a tesamorelin study. No published trial has compared fasted versus fed, or morning versus bedtime, dosing of tesamorelin, so any such difference has never been measured. This describes a regulator-reviewed prescription drug: our product is a research reagent, not intended for administration to a person.

Question 23

How does the cost of research-grade tesamorelin compare to the FDA-approved brand Egrifta?

Accepted Answer

Egrifta is a branded, FDA-approved prescription medicine, and branded drugs in the growth-hormone-axis space are typically priced far above any research chemical, reflecting the cost of the clinical-trial program, regulatory review, pharmaceutical-grade manufacturing and patent exclusivity built into the list price. A vial sold for laboratory research is priced as an unregulated peptide commodity, with none of that regulatory infrastructure behind it, so the price gap is not a discount on the same product. Our tesamorelin is sold strictly for in-vitro laboratory research, never as a substitute for Egrifta or any other prescription medicine, and not for the treatment, prevention or management of any condition in a person.

Question 24

Were the tesamorelin trials conducted in women as well as men, and did outcomes differ by sex?

Accepted Answer

The pivotal phase 3 trials enrolled HIV-positive adults with lipodystrophy, a population that skewed heavily male, consistent with the demographics of the HIV-associated lipodystrophy cohorts studied at the time. Those trials were not designed or powered to compare outcomes by sex, and no published subgroup analysis reports whether the visceral-fat or IGF-1 response differed between men and women. The later cognition trial recruited older adults from the general population rather than an HIV cohort and included both sexes, but again did not report a sex-based comparison of outcomes. Whether tesamorelin's effects differ by sex is a genuine evidence gap, not something the published literature has answered.

Question 25

What does the published research say about combining tesamorelin with GLP-1 medicines like tirzepatide or semaglutide?

Accepted Answer

No published trial has tested tesamorelin alongside tirzepatide or semaglutide, so there is no research evidence on what that combination does, in humans or otherwise, for safety or for any outcome. Tirzepatide and semaglutide are also EU-regulated, prescription-only medicines for approved metabolic indications, and any decision to combine them with anything belongs to a licensed physician managing that prescription, not to a research-chemical vendor. Our tesamorelin is sold strictly for in-vitro laboratory research, not marketed for fat loss or weight management, and not intended for administration to a person. Readers can see what has actually been studied on our /research/tesamorelin page and the original PubMed papers cited there.

Question 26

Do you provide injection-site rotation or administration instructions for tesamorelin?

Accepted Answer

No. Tesamorelin is sold strictly for in-vitro laboratory research, not for use in a person or animal, so we do not give injection site, needle, rotation, or timing guidance. For study design, the cited human trials describe subcutaneous injection as the route used in that published research; see our /research/tesamorelin page and its linked PubMed entries for the protocols themselves. Reconstitution volume and concentration for lab handling are covered separately on the product page, and are not injection instructions.

Question 27

Where should I keep the vial before I reconstitute it?

Accepted Answer

In the fridge, from the day it arrives. This is the step people skip most often, because a sealed freeze-dried vial looks robust enough to leave in a drawer. The dry cake in these GHRH-family vials is thin and porous, and warmth combined with humidity makes it slump and densify. A collapsed cake then dissolves slowly or incompletely and can leave a haze or floating particles when you finally add water, even when the powder itself still assays perfectly. So put the vial in the fridge at 2 to 8 degrees Celsius on the day the parcel arrives, or in the freezer at -20 degrees if it will sit unused for more than a couple of weeks, and keep it dark either way. Let it come back to room temperature before you add water. Once reconstituted it stays in the fridge and never goes into the freezer, because freeze-thaw cycles are harder on a dissolved peptide than steady cold. The few days in transit at ambient temperature are expected and fine; it is the weeks afterwards that decide how well it dissolves.

Question 28

Does the bacteriostatic water I use actually matter?

Accepted Answer

More than most people expect, and the reason is the specification rather than the brand. Bacteriostatic water is permitted a wide window: the USP range is pH 4.5 to 7.0, so two bottles that both say 0.9% benzyl alcohol can sit at opposite ends of it. Most labels state the benzyl alcohol and nothing else, so you cannot tell where yours sits. That matters because a peptide is least soluble near its own isoelectric point, and a water that drifts to one edge of the range can push a sensitive peptide toward it, which shows up as haze or particles that no amount of swirling fixes. We know this first-hand: one of our own past water batches measured pH 3.8 on a meter, below the permitted floor, and it turned GLP-1 peptides milky regardless of technique. Our own bacteriostatic water now comes from a European manufacturer whose batches run pH 6.2 to 6.4, with the measured value for the specific batch stated on its certificate rather than just a pass mark. Whichever water you use, take a freshly opened vial, keep it at room temperature and out of the light, and do not reuse a bottle that has been open for months.

Question 29

Why can Tesamorelin gel or turn cloudy during reconstitution, and how do I reconstitute it correctly?

Accepted Answer

Tesamorelin is one of the more reconstitution-sensitive peptides in our range. It is a GHRH analog, and formulation studies on this peptide family found aqueous solutions most stable in the mildly acidic pH 4 to 5 zone, while the approved pharmaceutical version is reconstituted in plain sterile water with an accepted solution pH of 4.5 to 7.4. Our bacteriostatic water sits at pH 6.2 to 6.4 (the measured value of each batch is on its certificate), within specification but at the upper edge of that comfort zone, so this peptide forgives far fewer technique errors than robust compounds. Use a generous volume (2 to 3 ml per 10 mg vial: lower concentration dissolves more easily), run the water slowly down the inside wall, swirl gently, never shake, and judge clarity only after 10 to 15 minutes of rest. If cloudiness or gel appears, lowering the pH helps: replace part of the water with a dilute acetic-acid diluent such as our Acetic Acid Water. Correct technique and a suitable diluent are part of the reconstitution work that lies with the researcher; a vial is not defective simply because a high-concentration or high-pH mix turned cloudy.

Question 30

How do I reconstitute Tesamorelin step by step with acetic-acid water?

Accepted Answer

Acid first, then top up; Tesamorelin usually needs a little less acid than AOD-9604. Choose your end volume (2 to 3 ml per 10 mg vial). First run 0.2 to 0.4 ml of dilute acetic-acid water, for example our Acetic Acid Water, slowly down the inside wall and swirl gently until the powder has visibly dissolved, which can take a few minutes. Only then top up to the end volume with bacteriostatic water and swirl gently once more, never shake, and judge clarity after 10 to 15 minutes of rest. The finished mix typically sits in the mildly acidic range (roughly pH 4.5 to 5.2 as a guide, depending on your water), which suits the GHRH family. The reason for the order: the powder should dissolve in the most favorable, acidic environment. A gel that has already formed in near-neutral water can rarely be rescued with acid afterwards.

Question 31

Does unrefrigerated shipping affect the quality of this product?

Accepted Answer

No. This product ships as a lyophilized (freeze-dried) powder in a sealed vial. Freeze-drying removes the water that drives peptide degradation, so the dry powder remains stable at room temperature for extended periods, longer than any normal parcel transit. Ambient shipping is standard practice across the peptide industry, and a peer-reviewed study reported months of room-temperature stability for a lyophilized therapeutic peptide (teriparatide, PMID 26620825). For comparison, FDA labeling allows an Ozempic (semaglutide) pen, after first use, to be kept out of the fridge for 56 days at 15 to 30°C, and a Mounjaro (tirzepatide) pen for up to 21 days at up to 30°C, even though these are ready-mixed solutions rather than sealed dry powder. Store the sealed vial in the fridge or freezer for long-term storage, and always refrigerate after reconstitution.

Question 32

Is there any evidence for Tesamorelin reducing visceral fat when used alongside Retatrutide or tirzepatide?

Accepted Answer

For the combination: none was identified, no trial testing tesamorelin with any GLP-1-class drug, in any species. What exists are three separate single-drug literatures that the stack idea splices together. Tesamorelin's visceral-fat effect is real but population-specific: in HIV-associated lipodystrophy, 26 weeks reduced visceral adipose tissue by about 34 square centimetres versus placebo (PMID 25038357), a condition of drug-associated central fat accumulation, not ordinary post-diet stubborn belly fat. Retatrutide has its own direct visceral-fat imaging data: in the MASLD substudy of the phase 2 trial, VAT fell roughly 14 to 48 percent depending on dose and time, versus a slight increase on placebo (PMID 38858523). Tirzepatide reduced MRI-measured visceral fat versus insulin degludec in type 2 diabetes (PMID 35468325), and the GLP-1 class shows a consistent VAT reduction across 30 randomized trials (PMID 37616255). Which frames the stack question honestly: the GLP-1-class drug is already doing, at documented scale, the thing tesamorelin is being added for, and whether adding a GHRH analogue on top changes visceral-fat outcomes, or safety, was not measured in any identified study. Anyone quoting a specific 'tesamorelin plus GLP-1' synergy number is quoting something we could not find in any published source. Both compounds on this shop are research materials; tesamorelin's approved indication belongs to the US product (Egrifta SV: reduction of excess abdominal fat in HIV-infected adults with lipodystrophy, with the label stating it is not indicated for weight-loss management), and retatrutide has no approval anywhere.

Question 33

Why does tesamorelin cost more per mg than other GH-axis research peptides like CJC-1295 or Ipamorelin?

Accepted Answer

The documented cost drivers are synthesis-side, though no audited per-peptide cost comparison was found, so this is directional rather than accounting. Peptides are built residue by residue, and commercial synthesis is priced that way, per amino acid, with surcharges for non-standard building blocks and modifications. Tesamorelin is the longest chain in this group and carries an N-terminal modification: the full 44-amino-acid GHRH sequence carrying an N-terminal trans-3-hexenoyl modification (about 5,136 daltons). CJC-1295 no-DAC and sermorelin are 29-residue chains (around 3,360 daltons), and ipamorelin is a 5-residue pentapeptide (712 daltons), roughly one-seventh of tesamorelin's mass, though ipamorelin's several non-standard D-amino-acid residues add their own surcharges, which is why chain length alone does not map linearly onto price. Longer chains also cost more than proportionally: manufacturers document reduced synthesis loading and falling cumulative yields for chains beyond 30 to 40 residues, since every additional coupling step multiplies losses that purification must then recover. Our own pricing tracks these input differences alongside ordinary supplier pricing and margin, not any potency ranking, currently about 6.50 euros per mg for tesamorelin against roughly 4 to 6 euros per mg for the shorter GH-axis peptides in 10 mg vials. What the price difference does NOT encode: evidence quality or 'strength'; tesamorelin happens to also carry the deepest clinical dataset of the group, but that is a property of its trial history, not of its cost per milligram, and per-mg price says nothing about which molecule fits a given research question.

Question 34

Tesamorelin and CJC-1295 are both GHRH analogs: has combining them, or pairing tesamorelin with a GHRP like ipamorelin, been studied?

Accepted Answer

No publication was identified testing either pairing: tesamorelin with CJC-1295 surfaces only in doping-detection chemistry, and tesamorelin with ipamorelin not at all. The receptor logic, which is what the community actually argues about, splits the two pairings differently. Tesamorelin plus CJC-1295 means two agonists of the SAME receptor, the GHRH receptor; whether doubling up produces addition, competition or nothing was not identified for this or any other GHRH-analog pair in our search, and the pituitary's feedback physiology gives no reason to assume two same-receptor agonists stack linearly. Tesamorelin plus ipamorelin pairs DIFFERENT receptors, GHRH receptor plus the ghrelin-type GHS receptor (ipamorelin's founding pharmacology, PMID 9849822), and for that architecture a real precedent exists in older clinical physiology: GHRH given with GHRP-6 produced markedly larger GH release than either alone in human studies (PMID 7783658). Honest boundaries on that precedent: it used different molecules (native GHRH and GHRP-6, not tesamorelin and ipamorelin), in acute physiology settings, and the specific multiplier figures circulating in vendor content for such combinations could not be verified against any indexed source. So: the different-receptor pairing has borrowed plausibility from real cousin data, the same-receptor pairing has none, and no direct study of either was identified, which also means combined tolerability, IGF-1 response and safety are unmeasured for both.

Tesamorelin

What is Tesamorelin

How it works

Often studied alongside

Documentation

Storage and stability

Reviews

Frequently Asked Questions

Technical data sheet

Frequently bought together

Retatrutide

AOD-9604

Sermorelin

Bacteriostatic Water

Lab Measuring Syringe + Prep Wipes Set (1 mL 31G)

Graduated Measuring Syringe 1 mL 31G x 6 mm

Alcohol Prep Pads 30 x 65 mm

Peptide Storage Box (10 Compartments)

Peptide Vial Case 30 Slots